Peginterferon Beta‑1a
| Product Overview |
| Generic Name | Peginterferon Beta‑1a |
| Brand Name(s) | Plegridy |
| Form | Subcutaneous/intramuscular Injection; |
| Strength | 125 µg per 0.5 mL dose |
| Therapeutic Class | Interferon beta, immunostimulant |
| ATC Code | L03AB11 |
| Manufacturing & Regulatory |
| Manufacturer | Biogen (originator); Eisai Pharma India |
| Country | USA, Switzerland, India, UK |
| GMP Compliance | WHO-GMP compliance |
| DMF/CEP | Type II DMF |
| COFEPRIS | Registered in Mexico |
| Free Sale Certificate | can provide upon request |
| Logistics & Export |
| MOQ | 24 vials |
| Shelf Life | 24 Months |
| Storage | 2–8 °C; protect from light; do not freeze, allow warming to room temperature before administration |
| Incoterms | FOB / CIF / DDP standard |
| Lead Time | 2 Weeks |
| Documentation |
| Certificate of Analysis (COA) | Yes, Upon Request |
| SDS | Yes – includes immunomodulator handling protocol and safety sections for injectable use |
| CTD Summary | full CTD proprietary and accessible under NDA/licensing |
Description
Indications & Usage: Indicated for relapsing forms of multiple sclerosis (relapsing‑remitting, clinically isolated syndrome, and active secondary progressive MS) with every‑2‑week dosing regime to reduce relapse frequency and delay disability progression
Request for Quote
